Imperial College London

DrTonyTarragona-Fiol

Faculty of MedicineDepartment of Surgery & Cancer

Divisional Manager
 
 
 
//

Contact

 

+44 (0)20 3312 7619t.tarragona

 
 
//

Location

 

1030Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

42 results found

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JLet al., 2012, A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults, PLoS One, Vol: 7, ISSN: 1932-6203

Journal article

Njai HF, Gombe B, Khamis T, Birungi J, Ruzagira E, Admassu D, Tarragona-Fiol T, Porter K, Stevens G, Mugisha J, Gilmour J, Kamali A, Kaleebu Pet al., 2011, Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials, LABMEDICINE, Vol: 42, Pages: 711-718, ISSN: 0007-5027

Journal article

Cox JH, Hayes P, Cormier E, Gill D, Kopycinski J, Spentzou A, Hachaambwa L, Bunce C, Sayeed E, Lombardo A, Komaroff W, Loughran K, Barin B, Dally L, Ackland J, Tarragona T, Keefer M, Excler J, Fast P, Gilmour Jet al., 2011, T-Cell Responses Induced by Immunization with Ad35-HIV-1 Vaccines Are Broad, Durable, Polyfunctional and Can Mediate Inhibition of HIV, Conference on AIDS Vaccine, Publisher: MARY ANN LIEBERT INC, Pages: A20-A20, ISSN: 0889-2229

Conference paper

Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DDet al., 2011, In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers, PLOS ONE, Vol: 6, ISSN: 1932-6203

Journal article

Keefer M, Hachaambwa L, Bunce C, Cox J, Sayeed E, Lombardo A, Komaroff W, Loughran K, Barin B, Ackland J, Cormier E, Hayes P, Tarragona T, Gilmour J, Excler J, Fast Pet al., 2010, Preliminary results of safety and immunogenicity of Ad35-GRIN/ENV HIV Vaccine in HIV-uninfected subjects (IAVI B001), AIDS Vaccine 2010, Publisher: MARY ANN LIEBERT INC, Pages: A16-A17, ISSN: 0889-2229

Conference paper

Mehendale S, Sahay S, Thakar M, Sahasrabuddhe S, Kakade M, Shete A, Shrotri A, Spentzou A, Tarragona T, Stevens G, Kochhar S, Excler JL, Fast P, Paranjape Ret al., 2010, Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India, INDIAN JOURNAL OF MEDICAL RESEARCH, Vol: 132, Pages: 168-175, ISSN: 0971-5916

Journal article

Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt Cet al., 2010, A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus, AIDS Res Hum Retroviruses, Vol: 26, Pages: 933-942, ISSN: 1931-8405

Journal article

Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour Jet al., 2010, Equivalence of ELISpot assays demonstrated between major HIV network laboratories, PLoS One, Vol: 5, ISSN: 1932-6203

Journal article

Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo Jet al., 2010, Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa, PLoS One, Vol: 5, ISSN: 1932-6203

Journal article

Howles S, Guimaraes-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, McMichael A, Dorrell Let al., 2010, Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects, Vaccine, Vol: 28, Pages: 7306-7312, ISSN: 1873-2518

Journal article

Stevens G, Chetty P, Stout J, Tarragona T, Stiles T, Molapo S, Roodt C, Khumalo L, Cox J, Gilmour Jet al., 2009, P06-07. A GCLP accredited Clinical Trial Laboratory Network in Africa and India: A collaborative effort between IAVI and in country research organizations, Retrovirology, Vol: 6

Journal article

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, DeHovitz J, Bekker L-G, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WCet al., 2009, Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm, JOURNAL OF VIROLOGY, Vol: 83, Pages: 7337-7348, ISSN: 0022-538X

Journal article

Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, Needham L, Ozaki D, Rodriguez-Chavez IR, Stevens G, Stiles T, Tarragona-Fiol T, Simkins Aet al., 2009, Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials, PLoS Medicine, Vol: 6, Pages: 1-5

Journal article

Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, Needham L, Ozaki D, Rodriguez-Chavez IR, Stevens G, Stiles T, Tarragona-Fiol T, Simkins Aet al., 2009, Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials, RETROVIROLOGY, Vol: 6, ISSN: 1742-4690

Journal article

Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast Pet al., 2009, A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers, AIDS Res Hum Retroviruses, Vol: 25, Pages: 1107-1116, ISSN: 1931-8405

Journal article

Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour Jet al., 2009, Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents, Clin Vaccine Immunol, Vol: 16, Pages: 147-155, ISSN: 1556-679X

Journal article

Gilmour J, Gill D, Huang Y, Carter D, Birungi J, Hayes P, Hahn B, Sato A, Tarragona T, Wan H, Sambor A, Levine G, Randles M, Cooper AR, Clark L, Self S, Koup R, Cox J, Wood B, Hural J, McElrath MJet al., 2008, Excellent Concordance between IFN-gamma ELISpot Assay Results in Two Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) Laboratories, AIDS Vaccine 2008 Conference, Publisher: MARY ANN LIEBERT INC, Pages: 137-137, ISSN: 0889-2229

Conference paper

Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Waruingi W, Odada J, Oyaro M, Indangasi J, Ndinya-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmour J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu Pet al., 2008, Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa, Pages: 2788-2795, ISSN: 0264-410X

The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.

Conference paper

Gilmour J, Stevens G, Gill D, Tarragona T, Seamons L, Birungi J, Kato PK, Semaganda A, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Ndzamela N, Thakar M, Pujari A, Purandare B, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Gotch F, Styles T, Stout J, Dally L, Boaz MJ, Hayes Pet al., 2007, Laboratory development and assay standardization for the evaluation of HIV vaccines in Africa and India, 6th Euroconference on Clinical Cell Analysis, Publisher: WILEY-LISS, Pages: 120-120, ISSN: 1552-4949

Conference paper

Barry SP, Walter J, Eftyhia V, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa G, Dally L, Klavinskis L, Farah B, Tarragona A, Alexandre B, Robinson A, Piterese C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo Jet al., 2007, Studies of a prophylactic HIV-1 vaccine candidate based on Modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity, Vaccine, Vol: 25, Pages: 2120-2127

Journal article

Gilmour J, Stevens G, Gill D, Tarragona T, Seamons LJ, Birungi J, Kato PK, Semaganda A, Anzala O, Farah Bet al., 2007, Laboratory development and assay standardization for the evaluation of HIV vaccines in Africa and India, Cytom part B-Clin CY, Vol: 72B, Pages: 120-120

Journal article

Bashir F, Ogola S, Idangasi J, Oyaro M, Onyango J, Gachie J, Tarragona T, Stevens G, Stout J, Anzala Oet al., 2007, Ensuring Good Clinical Laboratory Practice (GCLP) compliance during the conduct of HIV-1 Vaccine clinical trials at Kenya AIDS Vaccine Initiative (KAVI)., AIDS Vacinne 2007 Conference

Conference paper

Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo Jet al., 2007, Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity, Vaccine, Vol: 25, Pages: 2120-2127, ISSN: 0264-410X

Journal article

Bizimana J, Karita E, Boaz MJ, Tarragona T, Gilmour J, Stout J, Shutes E, Tekirya E, Musengamana V, Bekan BH, Hunter E, Allen Set al., 2006, Qualifying a vaccine trial laboratory in Rwanda for PBMC isolation,cryopreservation and shipping, HIV/AIDS Conference

Conference paper

Lima R, Mark D, Branch G, Muluubya A, Verlinde C, Tarragona T, Gilmour J, Fast P, Ketter Net al., 2005, Information and Communication Technology (ICT); a critical tool for HIV vaccine clinical trials in resource constrained settings, 3rd IAS Conference on HIV Pathogenesis and Treatment

Conference paper

Gotch F, Hayes P, Tarragona T, Gilmour J, Kebba Tet al., 2002, Testing the immunogenicity and potential efficacy of HIV vaccines, Second Euroconference on Clinical Cytometry From Pathogenesis to Therapy

Conference paper

Khan ZAJ, Feldman KA, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersch TGet al., 2001, P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases, J. Cancer Res Clin Oncol, Vol: 127, Pages: 675-680

Journal article

Khan ZAJ, Le-Marer N, Wharton RQ, Patel H, Araia R, Tarragona A, Ivison A, Allen-Mersh TGet al., 2000, Can a single tumor biopsy provide valid gene mutation information in colorectal cancer?, Gut, Vol: 46

Journal article

Khan ZAJ, Le Marer N, Wharton RQ, Patel H, Araia R, Tarragona A, Ivison A, Allen-Mersh TGet al., 2000, Can a single tumour biopsy provide valid p53 gene mutation information in colorectal cancer?, Gut, Vol: 46

Journal article

Khan ZAF, Jonas SK, Le Marer N, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersch TGet al., 2000, P53 Mutation in primary and metastatic tumours, and circulating tumour cells from colorectal carcinoma patients, Clinical Cancer Research, Vol: 6, Pages: 3499-3504

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00166308&limit=30&person=true